Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?
Journal
International journal of endocrinology
ISSN: 1687-8337
Titre abrégé: Int J Endocrinol
Pays: Egypt
ID NLM: 101516376
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
09
2019
revised:
25
11
2019
accepted:
02
12
2019
entrez:
16
5
2020
pubmed:
16
5
2020
medline:
16
5
2020
Statut:
epublish
Résumé
Hypogonadotropic hypogonadism (HH) can be sustained by organic or functional alterations of the hypothalamic-pituitary-testicular axis. Functional HH is related to systemic alterations, such as obesity or chronic inflammatory diseases, but could contribute to a negative course of the illness. For such situation, according to results obtained in infertile women, the administration of selective estrogen receptor modulators (SERMs) has been proposed in males too, with positive results on both metabolic and sexual function. This class of medications increases gonadotropin levels via antagonism to the estrogenic receptor; similar biological effects are also exerted by aromatase inhibitors (AIs), despite different mechanism of action. After a brief review of trials regarding SERMs and AIs use in male HH, we describe the structure and function of the androgen receptor (AR) as a basis for clinical research about compounds able to bind to AR, in order to obtain specific effects (SARMs). The tissue selectivity and different metabolic fate in comparison to testosterone can potentiate anabolic versus androgenic effects; therefore, they might be a valid alternative to testosterone replacement therapy avoiding the negative effects of testosterone (i.e., on prostate, liver, and hematopoiesis). Trials are still at an early phase of investigation and, at the moment, the application seems to be more useful for chronic disease with catabolic status while the validation as replacement for hypogonadism requires further studies.
Identifiants
pubmed: 32411230
doi: 10.1155/2020/9649838
pmc: PMC7201459
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
9649838Informations de copyright
Copyright © 2020 Vito A. Giagulli et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
J Gerontol A Biol Sci Med Sci. 2013 Oct;68(10):1226-35
pubmed: 22923429
Sex Med Rev. 2018 Jan;6(1):106-113
pubmed: 29174957
J Androl. 1991 Jul-Aug;12(4):258-63
pubmed: 1917692
J Urol. 2017 Apr;197(4):1127-1131
pubmed: 27984109
J Clin Endocrinol Metab. 1995 Dec;80(12):3689-98
pubmed: 8530621
Br J Clin Pharmacol. 2017 Oct;83(10):2179-2194
pubmed: 28449232
J Sex Med. 2014 Sep;11(9):2302-7
pubmed: 24902614
Bioorg Med Chem Lett. 1998 Apr 7;8(7):745-50
pubmed: 9871534
Mol Endocrinol. 1988 Dec;2(12):1265-75
pubmed: 3216866
BJU Int. 2016 Dec;118(6):994-1000
pubmed: 27226135
Br J Pharmacol. 2008 Jun;154(3):598-605
pubmed: 18500381
Psychoneuroendocrinology. 2010 Oct;35(9):1416-21
pubmed: 20471178
Mol Cell Endocrinol. 2012 Jul 6;358(1):1-8
pubmed: 22406839
J Clin Oncol. 2002 Jul 1;20(13):3001-15
pubmed: 12089231
Int J Impot Res. 2003 Jun;15(3):156-65
pubmed: 12904801
J Clin Endocrinol Metab. 2016 May;101(5):2040-6
pubmed: 26967690
J Clin Endocrinol Metab. 2009 Dec;94(12):4785-92
pubmed: 19820017
J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):87-95
pubmed: 22459616
J Clin Endocrinol Metab. 2000 Jan;85(1):219-23
pubmed: 10634390
Asian J Androl. 2016 May-Jun;18(3):435-40
pubmed: 26908066
PLoS One. 2017 Sep 8;12(9):e0183369
pubmed: 28886024
Curr Opin Clin Nutr Metab Care. 2009 May;12(3):232-40
pubmed: 19357508
J Med Chem. 1999 Jan 28;42(2):210-2
pubmed: 9925725
Andrology. 2013 Sep;1(5):749-57
pubmed: 23970453
Lancet Child Adolesc Health. 2019 Feb;3(2):109-120
pubmed: 30612946
J Clin Endocrinol Metab. 2010 Apr;95(4):1810-8
pubmed: 20173018
J Clin Endocrinol Metab. 2001 Jan;86(1):192-9
pubmed: 11232000
J Clin Endocrinol Metab. 2004 Mar;89(3):1174-80
pubmed: 15001605
J Sex Med. 2015 Aug;12(8):1761-9
pubmed: 26176805
Horm Res. 2009;72(6):321-30
pubmed: 19844120
J Clin Endocrinol Metab. 1998 Sep;83(9):3155-62
pubmed: 9745419
Endocrinology. 2007 Jan;148(1):363-73
pubmed: 17023534
J Musculoskelet Neuronal Interact. 2002 Mar;2(3):222-4
pubmed: 15758439
J Clin Endocrinol Metab. 2017 Mar 1;102(3):1067-1075
pubmed: 28359097
Nat Med. 2004 Jan;10(1):33-9
pubmed: 14702632
J Clin Endocrinol Metab. 1995 Dec;80(12):3546-52
pubmed: 8530597
Eur J Med Chem. 2002 Aug;37(8):619-34
pubmed: 12161060
Br J Pharmacol. 2008 Jun;154(3):502-21
pubmed: 18500378
Andrology. 2018 May;6(3):455-464
pubmed: 29527831
J Urol. 2014 Sep;192(3):875-9
pubmed: 24657837
J Biol Chem. 2001 Mar 9;276(10):7493-9
pubmed: 11102454
J Clin Endocrinol Metab. 2005 Oct;90(10):5717-22
pubmed: 16046582
Endocr Pract. 2017 Mar;23(3):279-287
pubmed: 27849376
J Clin Endocrinol Metab. 2018 May 1;103(5):1715-1744
pubmed: 29562364
Med J Aust. 2016 Sep 5;205(5):228-31
pubmed: 27581270
Arch Endocrinol Metab. 2018 Mar-Apr;62(2):227-235
pubmed: 29768628
Endocr Rev. 1995 Feb;16(1):87-116
pubmed: 7758434
J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):153-161
pubmed: 22031847
J Clin Endocrinol Metab. 2015 Feb;100(2):342-62
pubmed: 25590212
N Engl J Med. 1996 Mar 14;334(11):707-14
pubmed: 8594431
Endocrinology. 2010 Aug;151(8):3706-19
pubmed: 20534726
Eur J Endocrinol. 2016 Mar;174(3):R99-116
pubmed: 26537862
Biochem Biophys Res Commun. 1998 Mar 6;244(1):1-4
pubmed: 9514878
Cancer Lett. 2006 Jan 8;231(1):12-9
pubmed: 16356826
Mol Cell Endocrinol. 2013 Apr 30;369(1-2):52-62
pubmed: 23395916
Expert Opin Ther Pat. 2009 Sep;19(9):1239-58
pubmed: 19505196
Pharmacol Ther. 2019 Aug;200:135-147
pubmed: 31077689
J Clin Endocrinol Metab. 2018 Sep 1;103(9):3215-3224
pubmed: 29982690
Diabetes Care. 2010 Aug;33(8):1831-3
pubmed: 20484128
J Histochem Cytochem. 1993 May;41(5):671-8
pubmed: 8468448
J Clin Endocrinol Metab. 1999 Aug;84(8):2647-53
pubmed: 10443654
J Clin Endocrinol Metab. 1999 Oct;84(10):3459-62
pubmed: 10522980
Endocrinology. 2009 Mar;150(3):1259-68
pubmed: 18948405
Mol Endocrinol. 1995 Feb;9(2):208-18
pubmed: 7776971
Cancer Res. 2015 Sep 1;75(17):3663-71
pubmed: 26060018